Clinical trials
Completed Phase 4 Renal Insufficiency, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
153 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 6 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 2 |
| 2008 | 15 |
| 2009 | 17 |
| 2010 | 10 |
| 2011 | 10 |
| 2012 | 9 |
| 2013 | 11 |
| 2014 | 2 |
| 2015 | 11 |
| 2016 | 7 |
| 2017 | 6 |
| 2018 | 5 |
| 2019 | 3 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 153 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 10 |
| Abbott | 4 |
| Federico II University | 3 |
| Indiana University | 3 |
| Seoul National University Hospital | 3 |
| VA Office of Research and Development | 3 |
| Astellas Pharma Inc | 2 |
| AstraZeneca | 2 |
| Chang Gung Memorial Hospital | 2 |
| Dong-A University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency, Chronic | 153 |
| Anemia | 16 |
| Hyperparathyroidism, Secondary | 14 |
| Renal Insufficiency | 13 |
| Kidney Failure, Chronic | 12 |
| Hypertension | 11 |
| Kidney Diseases | 10 |
| Proteinuria | 9 |
| Anemia, Iron-Deficiency | 7 |
| Diabetes Mellitus, Type 2 | 7 |
Trials
Showing 1 to 25 of 153. Each trial links to its page on Pharma Observatory.
53 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.